Cheunkarndee Tia, Guo Matthew Z, Birkness-Gartman Jacqueline E, Oshima Kiyoko, Lin Cheng Ting, Marrone Kristen A
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Gastrointestinal and Liver Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
JTO Clin Res Rep. 2022 Dec 16;4(2):100448. doi: 10.1016/j.jtocrr.2022.100448. eCollection 2023 Feb.
As novel therapeutic regimens continue to lead to increased survival of patients with lung cancer, it is imperative to remain mindful of the accompanying increase in the incidence of new primary malignancies. Although the most common secondary malignancies in patients with lung cancer have historically included colon, rectal, esophageal, and thyroid cancers, we report here two rare cases of new primary hepatocellular carcinomas in patients receiving immune checkpoint inhibitor therapy for NSCLC. In both cases, the diagnosis of hepatocellular carcinoma, rather than assuming a hepatic metastasis, was crucial for determining the appropriate approach for treatment. These cases thus underscore the importance of appropriate diagnostics to ensure that the proper therapeutics are chosen and present important considerations for the lung cancer community going forward.
随着新型治疗方案不断提高肺癌患者的生存率，必须时刻留意新原发性恶性肿瘤发病率随之增加的情况。虽然肺癌患者中最常见的继发性恶性肿瘤历来包括结肠癌、直肠癌、食管癌和甲状腺癌，但我们在此报告两例接受免疫检查点抑制剂治疗非小细胞肺癌的患者发生新原发性肝细胞癌的罕见病例。在这两例病例中，肝细胞癌的诊断（而非假定为肝转移）对于确定合适的治疗方法至关重要。因此，这些病例强调了适当诊断的重要性，以确保选择正确的治疗方法，并为肺癌领域未来的发展提供了重要的思考方向。
